Primary sclerosing cholangitis: resect, dilate, or transplant?

Area of Science:

• Hepatology
• Gastroenterology
• Surgical Oncology

Background:

• Primary sclerosing cholangitis (PSC) is a chronic inflammatory liver disease.
• PSC can progress to secondary biliary cirrhosis, necessitating effective management strategies.
• Optimal treatment for PSC before cirrhosis development remains an area of investigation.

Purpose of the Study:

• To compare the efficacy of extrahepatic biliary resection, endoscopic dilation, and liver transplantation in managing PSC.
• To evaluate survival rates and complications associated with different PSC treatment modalities.
• To determine the best treatment approach based on disease stage (cirrhotic vs. noncirrhotic).

Main Methods:

• A retrospective study of 146 PSC patients from 1980-1994.
• Management options included biliary resection with stenting, endoscopic dilation with stenting, medical therapy, and liver transplantation.
• Outcomes assessed included morbidity, mortality, bilirubin levels, survival, and cholangiocarcinoma development.

Main Results:

• Morbidity and mortality were comparable between surgical resection and nonoperative management.
• Noncirrhotic patients showed significantly improved bilirubin levels and 5-year survival with resection compared to nonoperative methods.
• Liver transplantation provided superior survival for cirrhotic PSC patients.
• Cholangiocarcinoma developed in 6% of nonoperatively managed patients but none of the resected patients.

Conclusions:

• Extrahepatic biliary resection with long-term stenting is a viable option for select noncirrhotic PSC patients.
• Liver transplantation is the preferred treatment for PSC patients with cirrhosis.
• Resection may reduce the risk of cholangiocarcinoma in PSC.